现代药物与临床2024,Vol.39Issue(12) :3271-3274.DOI:10.7501/j.issn.1674-5515.2024.12.044

促分泌剂治疗便秘型肠易激综合征的研究进展

Research progress on secretagogues in treatment of constipation-predominant irritable bowel syndrome

王一琼 高鸿智 梁磊 杨勇军
现代药物与临床2024,Vol.39Issue(12) :3271-3274.DOI:10.7501/j.issn.1674-5515.2024.12.044

促分泌剂治疗便秘型肠易激综合征的研究进展

Research progress on secretagogues in treatment of constipation-predominant irritable bowel syndrome

王一琼 1高鸿智 2梁磊 3杨勇军1
扫码查看

作者信息

  • 1. 川北医学院附属医院 中西医结合肛肠科,四川 南充 637002
  • 2. 武汉经济技术开发区(汉南区)人民医院 外一科,湖北 武汉 430090
  • 3. 天津中医药大学,天津 301617
  • 折叠

摘要

便秘型肠易激综合征是一种以腹痛或腹部不适伴大便排出困难、排便周期延长为主要症状且常伴随焦虑、抑郁等精神症状的胃肠功能紊乱性疾病.促分泌剂可被用来治疗便秘型肠易激综合征,治疗便秘的同时也能够缓解腹痛.促分泌剂目前主要包括 3 类:氯离子通道激活剂、鸟苷酸环化酶C激活剂、强效小分子钠/氢交换体 3 抑制剂.总结了促分泌剂治疗便秘型肠易激综合征的作用机制、疗效和安全性,以期为临床应用提供参考.

Abstract

Constipation-predominant irritable bowel syndrome is a disorder of gastrointestinal function,which is characterized by abdominal pain or abdominal discomfort with difficulty defecation,prolonged defecation time interval,and mental symptoms such as anxiety and depression.Secretagogues can be used to treat constipation-predominant irritable bowel syndrome,which can alleviate abdominal pain while treating constipation.There are currently three main types of secretagogues:chloride channel activators,guanylate cyclase C activators,and potent small molecule sodium/hydrogen exchanger 3 inhibitors.This article summarizes the mechanism,efficacy,and safety of secretagogues in treatment of constipation-predominant irritable bowel syndrome,in order to provide reference for clinical application.

关键词

促分泌剂/便秘型肠易激综合征/氯离子通道激活剂/鸟苷酸环化酶C激活剂/钠/氢交换体3抑制剂

Key words

secretagogues/constipation-predominant irritable bowel syndrome/chloride channel activator/guanylate cyclase C activator/sodium/hydrogen exchanger 3 inhibitor

引用本文复制引用

出版年

2024
现代药物与临床
天津药物研究院,中国药学会

现代药物与临床

CSTPCD
影响因子:1.179
ISSN:1674-5515
段落导航相关论文